Clinical data of CU-201, CUDC-101 presented at EORTC-NCI-AACR Symposium Curis, Inc before pain attack . , a drug development business seeking to develop next era targeted small molecule medication candidates for tumor treatment, today announced the demonstration of data in two poster presentations at the 22nd EORTC-NCI-AACR Symposium on ‘Molecular Targets and Cancer Therapeutics,’ kept in Berlin, Germany, 16-19 November. One presentation is titled ‘Anti-Tumor Activity of CU-201, an Inhibitor of HDAC, SFK and Abl Kinases’ and was shown by Rudi Bao, M.D., Ph.D., Curis’ Senior Director of Oncology on November 17th. The other presentation is normally titled ‘The First-in-Human, First-in-Class Research of CUDC-101, a Multi-Targeted Inhibitor of HDAC, EGFR and HER2: A Phase I Research in Individuals with Advanced Tumor’ and was provided by Toshio Shimizu, M.D., Ph. D., Visiting Clinical Fellow, South Texas Accelerated Study Therapeutics on November 18th. We are extremely pleased that CUDC-101 has been shown to become well tolerated at pharmacologically meaningful concentrations, and we are encouraged by evidence of its biological activity observed in this first-in-human Phase I study,’ stated Dan Passeri, Curis President and Chief Executive Officer. ‘We also be prepared to move extra network-targeted brokers from our proprietary portfolio into scientific studies in the near future,’ Mr. Passeri continuing. ‘In 2011, we be prepared to select at least one fresh development candidate, and so are continuing research in substances targeting HDAC and PI3 kinase and also in CU-201 and other molecules from this class. We are also exploring potential advancement collaborations around CU-201 and related substances currently.’ Curis’ discovery and development efforts are focused on building a portfolio of small molecule network-targeted inhibitors against a wide range of cancer types. Compounds within each of Curis’ research and development applications are designed to inhibit a number of validated cancer targets, including EGFR, Her2, PI3K, Abl, SRC family kinases and others, along with the inhibition of histone deacetylase, or HDAC, a validated non-kinase cancer target. Each target mixture is chosen because of its potential of mechanistic synergy, a strategy designed to disrupt cancer resistance networks and offer a more durable response for the tumor individual. This potential breakthrough approach in cancers therapy differentiates Curis from other cancer-focused companies.
Clinical genomic sequencing could impact treatment decisions in advanced prostate cancer patients An international collaboration of researchers are advancing precision medicine to men with advanced prostate cancer. The researchers, led by Arul Chinnaiyan, M.D., Ph.D., and Charles L. Sawyers, M.D., co-leaders of the Stand Up to Cancer-Prostate Cancer Base Dream Team, sequenced the RNA and DNA of tumor biopsy samples from 150 men with metastatic castration resistant prostate cancer, an advanced cancer that has stopped giving an answer to standard hormone-based treatments. This is actually the first major analysis of the aggressive and common type of cancer in a clinical context. The scholarly study is published in Cell. Eight institutions from the United States and Europe contributed individual biopsies to two central sites that carried out the sequencing evaluation. One of the surprising results in this study was that approximately 90 % of situations harbored some kind of genetic anomaly that was clinically actionable, meaning we have potential treatments to target that particular aberration. This shows that medical genomic sequencing could effect treatment decisions in a significant number of individuals with disease, says co-senior author and principal investigator Arul Chinnaiyan, M.D., Ph.D., director of the Michigan Middle for Translational S and Pathology.P. Hicks Professor of Pathology at the University of Michigan Health System. Prior studies have viewed the genomic landscape of localized prostate cancer and found few actionable genomic alterations clinically. This is the first study to focus on this specific subtype clinically, which is certainly difficult to take care of because patients nearly always develop resistance to available treatments. Up to now, precision cancer medicine activities in advanced prostate malignancy have been limited by lack of ability to acquire clinical samples from sufferers at the time of failure of hormone treatment and too little comprehensive genomic data for potentially actionable alterations, explains Charles L. Sawyers, M.D., co-senior writer and seat of the Human Oncology and Pathogenesis System at Memorial Sloan Kettering Cancer tumor Center. This multi-institutional and international research demonstrates the feasibility of comprehensive and integrative genomics on prospective biopsies from individual sufferers to enable precision tumor medicine activities in this large individual population. The stage is set by This study for additional profiling initiatives which might enable biological discovery and have immediate therapeutic relevance, Sawyers adds. Related StoriesNew antenna-like device makes breast cancer surgery easier for surgeonsViralytics enters into scientific trial collaboration contract with MSDMD Anderson research reveals why chemotherapy medicines not effective for most pancreatic cancer patientsThe researchers found that almost all the tumors had a genetic aberration recognized to travel cancers. The most typical, found in two-thirds of the individuals nearly, were aberrations in the androgen receptor. This was likely to some extent since the hallmark of castration-resistant disease is definitely that it no longer responds to regular androgen-blocking therapies. But a great many other aberrations had been found as well. Fourteen % of patients had a mutation in the BRCA1 or BRCA2 gene, which are already recognized to increase risk of breast and ovarian cancer. A class of medicines called PARP inhibitors have been completely accepted in BRCA-positive ovarian malignancy, suggesting prospect of PARP inhibitors to play a role in prostate cancers with this type of aberration. Furthermore, the researchers discovered that 8 % of individuals acquired an inherited genetic alteration. This shows that genetic counseling might be befitting patients with prostate cancer. Among the unique areas of this study is that it utilized refreshing biopsy samples from living sufferers with metastatic castration resistant prostate malignancy. Typically it has been difficult to obtain a large enough quantity of quality tumor tissue, especially from bone biopsies, to make sequencing possible. As part of their Endure Cancer-Prostate Cancer Base grant, the experts shall sequence and follow a total of at least 500 patients. The procedure is expected by them to take several more years. Because they begin to discover more sufferers with androgen receptor mutations and other aberrations, the researchers desire to begin linking particular aberrations to response or level of resistance to specific treatments, producing precision medicine more relevant and effective for metastatic castration resistant prostate cancer.